The ASCO 2018 annual meeting: update on the adjuvant treatment of early breast cancer
| Autor: | Karl J. Aichberger, Clemens Dormann |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Clinical Oncology
Oncology medicine.medical_specialty business.industry medicine.medical_treatment Hematology medicine.disease 03 medical and health sciences 0302 clinical medicine Breast cancer Denosumab Ovarian function 030220 oncology & carcinogenesis Internal medicine medicine 030212 general & internal medicine business Adjuvant Early breast cancer medicine.drug |
| Zdroj: | memo - Magazine of European Medical Oncology. 11:272-275 |
| ISSN: | 1865-5076 1865-5041 |
| DOI: | 10.1007/s12254-018-0448-3 |
| Popis: | At this year’s American Society of Clinical Oncology (ASCO) annual meeting two large phase 3 trials, the ABCSG-18 and the D‑CARE study, analysed the effects of adjuvant denosumab in breast cancer patients and reported different outcomes. Another phase 3 study, the ASTRRA trial, investigated the use of adjuvant ovarian function suppression (OFS) in high-risk premenopausal patients. This trial confirmed the benefit of OFS similar to the results of the already published SOFT/TEXT trials but raises some crucial questions on the optimal duration of OFS in these patients. The results of the SOFT/TEXT trials were also updated at this meeting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink